Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Masson

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
Chemical Science|September 15, 2023
Solvent-controlled formation of alkali and alkali-earth-secured cucurbituril/guest trimersDoroteja Lončarić, Fahimeh Movahedifar, Jakub Radek Štoček, et al.
Journal of Clinical Pharmacology|February 26, 2013
Inhibitory effect of ketoconazole on the pharmacokinetics of a multireceptor tyrosine kinase inhibitor BMS-690514 in healthy participants: assessing the mechanism of the interaction with physiologically-based pharmacokinetic simulationsZheng Yang, Blisse Vakkalagadda, Guoxiang Shen, et al.
British Journal of Clinical Pharmacology|August 24, 2016
Use of a cocktail probe to assess potential drug interactions with cytochrome P450 after administration of belatacept, a costimulatory immunomodulatorDaphne Williams, Xiaolu Tao, Lili Zhu, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 18, 2012
Metabolic chiral inversion of brivanib and its relevance to safety and pharmacologyJiachang Gong, Jinping Gan, Eric Masson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2005
Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancerAnne L Thomas, Bruno Morgan, Mark A Horsfield, et al.
Cancer Chemotherapy and Pharmacology|May 31, 2013
The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinasesAnthony El-Khoueiry, James A Posey, Juan Ramón Castillo Ferrando, et al.
ACS Nano|April 18, 2025
Gating Single Molecules with CounterionsDaniel J Trainer, Kyaw Zin Latt, Xinyue Cheng, et al.
Inorganic Chemistry|July 28, 2023
Light- and Chemical-Doping-Induced Magnetic Behavior of Eu Molecular SystemsTijana Rajh, Eric Masson, Kyaw Zin Latt, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 11, 2022
An age-dependent mathematical model of neurofilament trafficking in healthy conditionsAlessio Paris, Pranami Bora, Silvia Parolo, et al.
Clinical Drug Investigation|November 13, 2013
Pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept in adult kidney transplant recipientsJinshan Shen, Robert Townsend, Xiaoli You, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Chemical Science|September 15, 2023
Solvent-controlled formation of alkali and alkali-earth-secured cucurbituril/guest trimersDoroteja Lončarić, Fahimeh Movahedifar, Jakub Radek Štoček, et al.
Journal of Clinical Pharmacology|February 26, 2013
Inhibitory effect of ketoconazole on the pharmacokinetics of a multireceptor tyrosine kinase inhibitor BMS-690514 in healthy participants: assessing the mechanism of the interaction with physiologically-based pharmacokinetic simulationsZheng Yang, Blisse Vakkalagadda, Guoxiang Shen, et al.
British Journal of Clinical Pharmacology|August 24, 2016
Use of a cocktail probe to assess potential drug interactions with cytochrome P450 after administration of belatacept, a costimulatory immunomodulatorDaphne Williams, Xiaolu Tao, Lili Zhu, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 18, 2012
Metabolic chiral inversion of brivanib and its relevance to safety and pharmacologyJiachang Gong, Jinping Gan, Eric Masson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2005
Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancerAnne L Thomas, Bruno Morgan, Mark A Horsfield, et al.
Cancer Chemotherapy and Pharmacology|May 31, 2013
The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinasesAnthony El-Khoueiry, James A Posey, Juan Ramón Castillo Ferrando, et al.
ACS Nano|April 18, 2025
Gating Single Molecules with CounterionsDaniel J Trainer, Kyaw Zin Latt, Xinyue Cheng, et al.
Inorganic Chemistry|July 28, 2023
Light- and Chemical-Doping-Induced Magnetic Behavior of Eu Molecular SystemsTijana Rajh, Eric Masson, Kyaw Zin Latt, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 11, 2022
An age-dependent mathematical model of neurofilament trafficking in healthy conditionsAlessio Paris, Pranami Bora, Silvia Parolo, et al.
Clinical Drug Investigation|November 13, 2013
Pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept in adult kidney transplant recipientsJinshan Shen, Robert Townsend, Xiaoli You, et al.
Pageof 8